Alice Zhang's 'all-in-human' AI and genomics upstart scores a $98M Series B
Paul Schloesser
Associate Editor
Just a few months after California AI and genomics player Verge Genomics partnered with Eli Lilly in a $700 million-plus biobucks deal for 4 neurological programs, the biotech has finished raising its next financing round — netting $98 million in equity funding with Lilly jumping on board as a new investor.
The South San Francisco-based, neuroscience-focused company announced the completion of the Series B this morning, which was led by BlackRock-managed funds and supported by some new big-name investors such as Eli Lilly, Merck’s Global Health Innovation Fund and Vulcan Capital. Some existing investors joined in as well, including ALS Investment Fund and Tao Capital Partners.